Century Therapeutics, Inc. (IPSC)

2,5600 -0,1200 (-4,48%) Al cierre: 04:00PM EDT

Century Therapeutics, Inc.

25 North 38th Street
11th Floor
Philadelphia, PA 19104
United States
267 817 5790
https://www.centurytx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 152

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Brent Pfeiffenberger M.B.A., Pharm.D.	CEO & Director	274,06k	N/A	N/A
Dr. Adrienne Farid Ph.D.	COO & Head of Early Development	670,29k	N/A	1962
Dr. Gregory Russotti Ph.D.	Chief Technology & Manufacturing Officer	852,56k	N/A	1967
Mr. Douglas Carr CPA	Interim Principal Financial Officer, Senior VP of Finance & Operations and Secretary	N/A	N/A	N/A
Mr. Kenneth J. Dow J.D.	Senior VP of General Counsel	N/A	N/A	N/A
Dr. Shane Williams Ph.D.	Chief People Officer	N/A	N/A	N/A
Dr. Hyam I. Levitsky M.D.	President of Research & Development	502,12k	N/A	1958
Michael Naso Ph.D.	Senior VP of Cell Engineering	N/A	N/A	N/A
Dr. Nick Trede M.D., Ph.D.	Senior VP & Head of Clinical Development	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Century Therapeutics, Inc., a día 1 de junio de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 5; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.